{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:59:35Z","timestamp":1790657975828,"version":"4.1.0"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Gastroenterol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer anorexia\u2013cachexia syndrome (CACS) is prevalent among patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C hepatocellular carcinoma (HCC) and is strongly associated with poor prognosis, reduced treatment tolerance, and impaired quality of life. Megestrol acetate (MA) has demonstrated efficacy in improving appetite and body weight; however, conventional formulations are limited by variable bioavailability. This trial will evaluate the efficacy and safety of nanocrystalline megestrol acetate (NMA) in patients with BCLC stage B or C HCC and pre-cachexia or cachexia receiving systemic therapy combined with transarterial chemoembolization (TACE) or hepatic arterial infusion chemotherapy (HAIC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicenter, randomized, open-label, parallel-group Phase II trial protocol will enroll 68 adults aged 18\u201375 years with BCLC stage B or C HCC and pre-cachexia or cachexia. Participants will be stratified according to BCLC stage and weight loss during the previous 6 months and then randomized in a 1:1 ratio to receive either NMA (625 mg\/day for 12 weeks) plus antitumor therapy (systemic therapy combined with transarterial chemoembolization [TACE] or hepatic arterial infusion chemotherapy [HAIC]) or antitumor therapy alone. Antitumor therapy will comprise systemic therapy combined with TACE or HAIC. The co-primary endpoints are the proportions of Anorexia\/Cachexia Subscale-12 (A\/CS-12) responders and body mass index (BMI) responders at Week 12. Secondary endpoints include objective response rate, progression-free survival, changes in the L3 skeletal muscle index (L3 SMI), and the incidence of adverse events. Exploratory endpoints will evaluate inflammatory and nutritional biomarkers as well as quality of life, assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial will provide preliminary comparative data on NMA plus antitumor therapy versus antitumor therapy alone in patients with BCLC stage B or C HCC and pre-cachexia or cachexia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics<\/jats:title>\n                    <jats:p>The study protocol was approved by the Ethics Committee of West China Hospital, Sichuan University (IRB No. 2025-2539). The trial is registered at ClinicalTrials.gov NCT07356037.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgstr.2026.1926294","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:47:35Z","timestamp":1790657255000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["NMA plus antitumor therapy versus antitumor therapy alone in patients with BCLC stage B or C hepatocellular carcinoma and pre-cachexia or cachexia: protocol for a prospective, multicenter, randomized, open-label phase II trial"],"prefix":"10.3389","volume":"5","author":[{"given":"Ruihong","family":"Dai","sequence":"first","affiliation":[{"name":"Interventional Diagnosis and Treatment Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Facheng","family":"Lu","sequence":"additional","affiliation":[{"name":"Interventional Diagnosis and Treatment Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibing","family":"Leng","sequence":"additional","affiliation":[{"name":"Interventional Diagnosis and Treatment Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"He","sequence":"additional","affiliation":[{"name":"Interventional Diagnosis and Treatment Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Guo","sequence":"additional","affiliation":[{"name":"Interventional Diagnosis and Treatment Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Hai","sequence":"additional","affiliation":[{"name":"Interventional Diagnosis and Treatment Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Interventional Diagnosis and Treatment Center, West China Hospital, Sichuan University","place":["Chengdu, Sichuan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-023-00734-5","article-title":"Cancer-associated cachexia - understanding the tumour macroenvironment and microenvironment to improve management","volume":"20","author":"Argil\u00e9s","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3156-8","article-title":"Quality of life and survival survey of cancer cachexia in advanced non-small cell lung cancer patients-Japan nutrition and QOL survey in patients with advanced non-small cell lung cancer study","volume":"24","author":"Takayama","year":"2016","journal-title":"Support Care Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/oncsis.2016.3","article-title":"Understanding cachexia as a cancer metabolism syndrome","volume":"5","author":"Porporato","year":"2016","journal-title":"Oncogenesis"},{"key":"B4","first-page":"1","article-title":"Hepatocellular carcinoma (HCC): Epidemiology, etiology and molecular classification","volume":"149","author":"Chidambaranathan-Reghupaty","year":"2021","journal-title":"Adv Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.09.022","article-title":"Cachexia is prevalent in patients with hepatocellular carcinoma and associated with worse prognosis","volume":"20","author":"Rich","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000544979","article-title":"Cachexia index as a prognostic indicator in patients with unresectable hepatocellular carcinoma receiving atezolizumab and bevacizumab therapy","author":"Nguyen","year":"2025","journal-title":"Oncology"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnesp.2025.02.018","article-title":"Cachexia is an independent predictor of mortality in patients with hepatocellular carcinoma on systemic targeted therapy","volume":"66","author":"Unome","year":"2025","journal-title":"Clin Nutr ESPEN"},{"key":"B8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41392-022-01235-0","article-title":"Transarterial chemoembolization with PD-(L)1 inhibitors plus molecular targeted therapies for hepatocellular carcinoma (CHANCE001)","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/as9.0000000000000057","article-title":"Conversion to resectability using transarterial chemoembolization combined with hepatic arterial infusion chemotherapy for initially unresectable hepatocellular carcinoma","volume":"2","author":"Li","year":"2021","journal-title":"Ann Surg Open"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1669856","article-title":"TACE-HAlC combined with Donafenib and immune checkpoint inhibitors for BCLC stage C HCC patients (THEME study): a retrospective IPTW-adjusted cohort study","volume":"16","author":"Yin","year":"2025","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101503","article-title":"Sarcopenia is a negative prognostic factor in patients undergoing transarterial chemoembolization (TACE) for hepatic Malignancies","volume":"11","author":"Loosen","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1515\/oncologie-2025-0025","article-title":"Impact of body mass index in patients with hepatocellular carcinoma treated with TACE combined with lenvatinib and PD-1 inhibitors","volume":"27","author":"Wang","year":"2025","journal-title":"Oncologie"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01454-0","article-title":"Cancer cachexia: molecular mechanisms and treatment strategies","volume":"16","author":"Setiawan","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.vph.2013.06.001","article-title":"Selective suppression of endothelial cytokine production by progesterone receptor","volume":"59","author":"Goddard","year":"2013","journal-title":"Vascul Pharmacol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"93","DOI":"10.17691\/stm2021.13.1.11","article-title":"Clinical use of progestins and their mechanisms of action: Present and future (Review)","volume":"13","author":"Fedotcheva","year":"2021","journal-title":"Sovrem Tekhnologii Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0014-2999(94)90229-1","article-title":"Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations","volume":"265","author":"McCarthy","year":"1994","journal-title":"Eur J Pharmacol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3322\/canjclin.52.2.72","article-title":"Cancer anorexia-cachexia syndrome: current issues in research and management","volume":"52","author":"Inui","year":"2002","journal-title":"CA Cancer J Clin"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1023\/a:1016212804288","article-title":"A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability","volume":"12","author":"Amidon","year":"1995","journal-title":"Pharm Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1023\/a:1011910801212","article-title":"Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs","volume":"15","author":"Galia","year":"1998","journal-title":"Pharm Res"},{"key":"B20","article-title":"Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension","volume":"4","author":"Deschamps","year":"2009","journal-title":"Int J Nanomedicine"},{"key":"B21","article-title":"Research progress on preparation technology of nanocrystal drugs","volume":"56","author":"Tian","year":"2021","journal-title":"Acta Pharm Sin"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-2025-866","article-title":"Significant weight gain benefits of nanocrystalline megestrol acetate for patients with cancer anorexia-cachexia syndrome","volume":"14","author":"Cheng","year":"2025","journal-title":"Transl Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdu086","article-title":"Validation of the consensus-definition for cancer cachexia and evaluation of a classification model--a study based on data from an international multicentre project (EPCRC-CSA)","volume":"25","author":"Blum","year":"2014","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(09)70200-1","article-title":"Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials","volume":"10","author":"Quinten","year":"2009","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.56.1894","article-title":"Diagnostic criteria for the classification of cancer-associated weight loss","volume":"33","author":"Martin","year":"2015","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.37.1021","article-title":"Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma","volume":"29","author":"Pawlik","year":"2011","journal-title":"J Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2013.05.011","article-title":"A randomised phase II study of TSU-68 in patients with hepatocellular carcinoma treated by transarterial chemoembolisation","volume":"49","author":"Inaba","year":"2013","journal-title":"Eur J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2020.02.021","article-title":"Home artificial nutrition in palliative care cancer patients: Impact on survival and performance status","volume":"39","author":"Ruggeri","year":"2020","journal-title":"Clin Nutr"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1993.11.4.762","article-title":"Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and\/or cachexia","volume":"11","author":"Loprinzi","year":"1993","journal-title":"J Clin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v106.11.1433.1433","article-title":"A pilot study comparing megestrol acetate concentrated suspension (MA-CS) to megestrol acetate oral suspension (MA-OS) on weight gain and body composition in patients with HIV-associated unintended weight loss (UWL)","volume":"106","author":"Cilla","year":"2005","journal-title":"Blood"}],"container-title":["Frontiers in Gastroenterology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1926294\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:47:45Z","timestamp":1790657265000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgstr.2026.1926294\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":31,"alternative-id":["10.3389\/fgstr.2026.1926294"],"URL":"https:\/\/doi.org\/10.3389\/fgstr.2026.1926294","relation":{},"ISSN":["2813-1169"],"issn-type":[{"value":"2813-1169","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"article-number":"1926294"}}